These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 35612829)

  • 1. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
    Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
    JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
    J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
    Lopez AT; Geskin L
    Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.
    Sadik CD; Langan EA; Gutzmer R; Fleischer MI; Loquai C; Reinhardt L; Meier F; Göppner D; Herbst RA; Zillikens D; Terheyden P
    Front Immunol; 2020; 11():588582. PubMed ID: 33708189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
    Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
    Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
    Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
    JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
    Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
    Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: A case series of 13 patients.
    Yun JSW; Chan OB; Goh M; McCormack CJ
    Australas J Dermatol; 2023 Feb; 64(1):131-137. PubMed ID: 36514287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review.
    Nadelmann ER; Yeh JE; Chen ST
    JAMA Oncol; 2022 Jan; 8(1):130-138. PubMed ID: 34709352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
    Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
    J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
    Guan S; Zhang L; Zhang J; Song W; Zhong D
    Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
    Naidoo J; Schindler K; Querfeld C; Busam K; Cunningham J; Page DB; Postow MA; Weinstein A; Lucas AS; Ciccolini KT; Quigley EA; Lesokhin AM; Paik PK; Chaft JE; Segal NH; D'Angelo SP; Dickson MA; Wolchok JD; Lacouture ME
    Cancer Immunol Res; 2016 May; 4(5):383-9. PubMed ID: 26928461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.
    Tsiogka A; Bauer JW; Patsatsi A
    Acta Derm Venereol; 2021 Jan; 101(1):adv00377. PubMed ID: 33426566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Programmed Death-1 Inhibitors-induced Bullous Pemphigoid in 21 Cases].
    Li S; He C; Zuo Y; Jin H
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Oct; 42(5):603-609. PubMed ID: 33131514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.
    Liu Y; Chen Y; Zeng Z; Liu A
    Cancer Med; 2023 Mar; 12(6):6637-6648. PubMed ID: 36426382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
    JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors.
    Vogrig A; Muñiz-Castrillo S; Joubert B; Picard G; Rogemond V; Skowron F; Egri M; Desestret V; Tilikete C; Psimaras D; Ducray F; Honnorat J
    Neurology; 2021 Feb; 96(6):e866-e875. PubMed ID: 33318162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.